JNJ

225.83

+0.51%↑

UNH

362.93

-1.54%↓

TMO

465.46

+0.37%↑

ISRG

449.53

-0.08%↓

ABT

87.22

-0.78%↓

JNJ

225.83

+0.51%↑

UNH

362.93

-1.54%↓

TMO

465.46

+0.37%↑

ISRG

449.53

-0.08%↓

ABT

87.22

-0.78%↓

JNJ

225.83

+0.51%↑

UNH

362.93

-1.54%↓

TMO

465.46

+0.37%↑

ISRG

449.53

-0.08%↓

ABT

87.22

-0.78%↓

JNJ

225.83

+0.51%↑

UNH

362.93

-1.54%↓

TMO

465.46

+0.37%↑

ISRG

449.53

-0.08%↓

ABT

87.22

-0.78%↓

JNJ

225.83

+0.51%↑

UNH

362.93

-1.54%↓

TMO

465.46

+0.37%↑

ISRG

449.53

-0.08%↓

ABT

87.22

-0.78%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR
Search

Immunocore Holdings PLC ADR

Aperta

28 0.32

Acquista

Aggiornamento del prezzo 1 mag 2026, 19:59 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.88

Massimo

28.3

Metriche Chiave

By Trading Economics

Entrata

-30M

-30M

Vendite

-26M

77M

Margine di Profitto

-38.823

Dipendenti

524

EBITDA

-12M

-8M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+122.55% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-212M

1.5B

Apertura precedente

27.68

Chiusura precedente

28

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

27.895 / 30.16 Supporto e resistenza

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 22:17 UTC

Utili

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

LeggI

4 mag 2026, 23:47 UTC

Utili

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

LeggI

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

LeggI

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

LeggI

4 mag 2026, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

LeggI

4 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

LeggI

4 mag 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

LeggI

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

LeggI

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

LeggI

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

LeggI

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

LeggI

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

DJ

LeggI

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

DJ

LeggI

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

DJ

LeggI

4 mag 2026, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

LeggI

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

LeggI

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

LeggI

4 mag 2026, 22:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

LeggI

4 mag 2026, 22:26 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

LeggI

4 mag 2026, 22:02 UTC

Utili

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

LeggI

4 mag 2026, 22:00 UTC

Discorsi di Mercato

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

LeggI

4 mag 2026, 21:52 UTC

Utili

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

LeggI

4 mag 2026, 21:50 UTC

Utili

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

LeggI

4 mag 2026, 21:50 UTC

Utili

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

LeggI

4 mag 2026, 21:49 UTC

Utili

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

LeggI

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

LeggI

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

LeggI

4 mag 2026, 21:43 UTC

Utili

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

LeggI

4 mag 2026, 21:41 UTC

Utili

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

LeggI

4 mag 2026, 21:40 UTC

Utili

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

122.55% in crescita

Previsioni per 12 mesi

Media 62.67 USD  122.55%

Alto 100 USD

Basso 33 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

6

Acquista

3

Mantieni

0

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

A breve termine

Weak Bearish Evidence

Recent bearish events outweigh bullish events.

A termine intermedio

Weak Bearish Evidence

Recent bearish events outweigh bullish events.

A lungo termine

Weak Bearish Evidence

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Altri titoli del settore

JNJ

Johnson and Johnson

225.83

↑ +0.51%

UNH

UnitedHealth Group Inc

362.93

↓-1.54%

TMO

Thermo Fisher Scientific Inc

465.46

↑ +0.37%

ISRG

Intuitive Surgical Inc

449.53

↓-0.08%

ABT

Abbott Laboratories

87.22

↓-0.78%
help-icon Live chat